Utility of ctDNA-Based Liquid Biopsy Testing in the Detection of Molecular Residual Disease and Recurrence in Patients with Early-Stage Non-Small Cell Lung Cancer



In the era of precision oncology, the use of liquid biopsy testing in patients with non-small cell lung cancer (NSCLC) and other solid cancers is rapidly evolving. Recent evidence has shown an increasing capability to detect circulating tumor DNA (ctDNA) in patients with localized, early-stage NSCLC with potential applications to personalize treatment decisions. However, detection of ctDNA continues to prove challenging. This webinar will discuss expert insights and summarize recent findings on how ctDNA testing can be applied to detect molecular residual disease (MRD) and early risk of relapse ahead of standard-of-care imaging surveillance. Are we ready to explore the potential applications of ctDNA-guided adjuvant trials in NSCLC?

In this webinar you will learn:
  • A clinician’s perspective and outlook on unmet medical need in early-stage NSCLC treatment paradigms, focusing on adjuvant and surveillance settings
  • Current clinical evidence for the use of MRD assessment in NSCLC clinical studies, how we can encourage uptake by clinicians/biopharma, and what needs to be done to enable clinical routine implementation
  • Evidence of ctDNA detection in early-stage NSCLC: results from the LUng cancer Circulating tumor DNA (LUCID) study
  • The current technology, emerging applications, and challenges of ctDNA
  • The key considerations of liquid biopsy-based MRD testing

Sponsored by Inivata

Добавить в избранное